ORTEXORTEX News
Tracking WEN? Get live short interest, options flow, and signals on ORTEX.Sign up free →
WE
ConfluenceWEN

Argus Downgrades Wendy's to Sell as Put Demand Spikes

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 30 Oct 2026, 10:52

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Why this matters: Argus Research flipped WEN from Buy to Sell on Thursday, a rare full two-notch downgrade on a stock already carrying 27.3% of its free float short. That call arrived the same day options traders pushed the put-call ratio to 0.2444, more than four standard deviations above its 20-day mean.

A week of converging pressure

Wendy's is up 9.1% over the past five days to $7.17. That bounce has not cooled bearish positioning. Short interest climbed to 52 million shares, 27.3% of free float, up 8.7% on the week and 8.1% on the month. Bears have added through the rally, not retreated from it.

The Argus downgrade is the sharpest analyst move in several months. Christine Dooley at Argus moved the rating directly from Buy to Sell with no target published. That followed UBS cutting its price target to $6.50 from $8.00 and Citigroup trimming to $6.75 from $8.25, both last week. The consensus is now Sell, with two Buy ratings against three Sells. Every firm that has revised a price target in October has gone lower. TD Cowen's $6.00 Hold is the lowest target in the set, sitting 16% below Thursday's close.

The options market made its own statement on the same day. The put-call ratio of 0.2444 is the highest reading in at least 20 sessions and compares with a 52-week low of 0.1836. The z-score of 4.1 reflects an unusual single-session surge in put volume relative to the stock's own recent pattern. The 52-week high for the ratio is 1.1393, so put positioning has not reached that kind of extreme yet, but the sharp one-day move is notable given how stable the ratio had been since early October.

Borrow market and the Nelson Peltz factor

Cost to borrow rose to 3.61%, up 51% over the past week and 40% over the past month. Availability stands at 30.1%, tightening from 36.5% a week ago. That is still considerably looser than the sub-20% readings seen in late September, so the borrow market is tight but not distressed. The ORTEX short score sits at 77.1, near its highest reading in the available history.

Set against that bearish configuration is Nelson Peltz. His 13D filing, last amended on 28 October, shows a stake of 16.23% of the class, or roughly 30.9 million shares. That is as of last disclosure. Trian Fund Management holds a further 7.8%. Together, the Peltz-aligned holding accounts for a substantial block of the register, limiting the float available for short sellers to target. The FINRA fortnightly figure puts days-to-cover at 9.95, a high reading that reflects how large the short position is relative to normal trading volume.

Earnings arrive on 5 November, six days away. The bear case, as framed in analyst research, centres on beef and chicken costs, roughly 40% of the food basket, alongside soft consumer confidence and 4.7x net debt to EBITDA leaving limited financial flexibility.

Data summary

  • Short interest: 27.3% of free float, up 8.7% on the week
  • Cost to borrow: 3.61%, up 51% week-on-week
  • Availability: 30.1%, down from 36.5% a week ago
  • Put-call ratio: 0.2444, z-score of 4.1 above the 20-day mean
  • Analyst consensus: Sell; lowest price target in the set is $6.00 (TD Cowen)
  • ORTEX short score: 77.1
  • Earnings: 5 November 2026

Stocks in this article

See the live data behind this article on ORTEX.

Open WEN on ORTEX →

How this article was generated

Generated
30 Oct 2026, 11:00
Data as of
30 Oct 2026, 10:52
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.